No
|
TR-111
|
82-28-0 |
1-Amino-2-methylanthraquinone |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-111
|
82-28-0 |
1-Amino-2-methylanthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Positive |
Positive |
ADENOMA OR ADENOCARCINOMA
|
Neoplastic Lesions
|
No
|
TR-111
|
82-28-0 |
1-Amino-2-methylanthraquinone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-111
|
82-28-0 |
1-Amino-2-methylanthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-111
|
82-28-0 |
1-Amino-2-methylanthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/50 16/50 27/50; SQUAMOUS CELL CARCINOMA 0/50 12/50 11/50
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 13/51 16/50; SQUAMOUS CELL CARCINOMA 0/50 12/51 13/50
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP (ADENOMA) 0/50 28/40 53/60 43/49; CARCINOMA 0/50 2/40 21/60 8/49
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP (ADENOMA) 0/50 13/40 51/59 40/50; CARCINOMA 0/50 1/40 11/59 17/50
|
Neoplastic Lesions
|
Yes
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 3/40 16/60 16/48 OR CARCINOMA 0/50 0/40 0/60 2/48
|
Neoplastic Lesions
|
Yes
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/50 10/40 11/59 14/50 OR CARCINOMA 0/50 0/40 2/59 1/50
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 6/50 45/50 49/50; CARCINOMA 0/50 23/50 27/50
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 10/50 38/51 39/50; CARCINOMA 9/50 18/51 21/50
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 28/40 47/60 29/48; CARCINOMA 0/50 12/40 57/60 45/48; HEPATOCHOLANGIOCARCINOMA 0/50 0/40 11/60 13/48
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 20/40 40/59 34/50; CARCINOMA 1/50 12/40 55/59 46/50; HEPATOCHOLANGIOCARCINOMA 0/50 0/40 6/59 2/50
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 4/50 17/50 13/49
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 7/50 26/51 24/50
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Urinary Bladder
|
Clear Evidence |
Clear Evidence |
TRANSITIONAL CELL PAPILLOMA 0/50 2/40 7/60 9/46; TRANSITIONAL CELL CARCINOMA 0/50 0/40 8/60 16/46
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Urinary Bladder
|
Clear Evidence |
Clear Evidence |
TRANSITIONAL CELL PAPILLOMA 0/50 1/38 2/58 8/50; TRANSITIONAL CELL CARCINOMA 0/50 0/38 1/58 4/50
|
Neoplastic Lesions
|
No
|
TR-456
|
147-47-7 |
1,2-Dihydro-2,2,4-trimethylquinoline (monomer) |
Mice |
Sencar |
Female |
Topical Application |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-456
|
147-47-7 |
1,2-Dihydro-2,2,4-trimethylquinoline (monomer) |
Mice |
B6C3F1 |
Female |
Topical Application |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-456
|
147-47-7 |
1,2-Dihydro-2,2,4-trimethylquinoline (monomer) |
Mice |
Sencar |
Male |
Topical Application |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-456
|
147-47-7 |
1,2-Dihydro-2,2,4-trimethylquinoline (monomer) |
Mice |
B6C3F1 |
Male |
Topical Application |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
Yes
|
TR-456
|
147-47-7 |
1,2-Dihydro-2,2,4-trimethylquinoline (monomer) |
Rats |
F344/N |
Male |
Topical Application |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOMA (SINGLE SECTIONS) 1/50 7/50 10/50 7/50 (STEP SECTIONS) 6/50 5/50 6/50 8/50 (COMBINED) 7/50 11/50 14/50 14/50; CARCINOMA (SINGLE SECTIONS) 0/50 1/50 0/50 0/50 (STEP SECTIONS) 0/50 1/50 0/50 0/50 (COMBINED) 0/50 1/50 0/50 0/50; ADENOMA OR CARCINOMA COMBINED (SINGLE SECTIONS) 1/50 8/50 10/50 7/50 (STEP SECTIONS) 6/50 6/50 6/50 8/50 (COMBINED) 7/50 12/50 14/50 14/50
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/46 10/46 13/50 10/51 OR CARCINOMA 0/46 0/46 4/50 6/51 COMBINED 5/46 10/46 17/50 15/51
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 23/50 18/51 29/55; SQUAMOUS CELL CARCINOMA 0/50 46/50 49/51 49/55
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 3/52 28/51 22/54 33/56; SQUAMOUS CELL CARCINOMA 0/52 40/51 50/54 51/56
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 13/49 32/51 17/52; SQUAMOUS CELL CARCINOMA 0/50 3/49 9/51 4/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 29/50 33/49 38/52; SQUAMOUS CELL CARCINOMA 0/50 9/50 27/49 13/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Female |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/50 6/50 7/51 10/55
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Male |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/52 2/51 10/54 11/56
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Intestines (Large)
|
Clear Evidence |
Equivocal Evidence |
ADENOCARCINOMA 0/49 0/47 1/52 2/52
|
May Have Been Related
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Intestines (Large)
|
Clear Evidence |
Equivocal Evidence |
ADENOCARCINOMA 0/50 0/50 2/48 1/52
|
May Have Been Related
|
Yes
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 20/49 21/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 6/50 9/50 8/51 31/55 OR CARCINOMA 1/50 3/50 0/51 2/55 COMBINED 7/50 11/50 8/51 31/55
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 11/52 18/51 21/54 29/56; CARCINOMA 13/52 24/51 24/54 31/56
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 1/50 6/49 12/52 21/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Male |
Gavage |
Oral Cavity
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/52 0/51 0/54 2/56
|
May Have Been Related
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL CARCINOMA 0/50 0/50 1/51 5/55
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 5/49 10/52 18/52 ; SQUAMOUS CELL CARCINOMA 0/50 1/49 21/52 21/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 4/50 9/49 19/52; SQUAMOUS CELL CARCINOMA 1/50 0/50 11/49 25/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Pancreas Acinar Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/50 21/50 36/49 29/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Preputial Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/49 3/47 5/49 11/50 OR CARCINOMA 0/49 3/47 3/49 5/50 COMBINED 5/49 6/47 8/49 16/50
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Female |
Gavage |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 0/51 3/54; ADENOCARCINOMA 0/50 4/50 3/51 6/54; POLYP 0/50 2/50 1/51 6/54
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/60 1/59 0/60 4/60
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/60 0/60 0/59 3/60
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Brain
|
Clear Evidence |
Clear Evidence |
(STOP STUDY) GLIOMA 0/50 2/50 0/50 1/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA OR CARCINOMA 0/50 0/50 3/50 2/50 4/50 22/80
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA OR CARCINOMA 1/50 0/50 0/50 1/50 8/50 4/73, STOP STUDY 3/50 7/50 9/50 10/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 8/50 10/50 7/50 15/50 20/50 9/80
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 6/50 7/50 9/50 20/50 31/50 6/73, STOP STUDY 27/50 23/50 30/50 13/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LYMPHOMA 6/50 12/50 11/50 7/50 9/50 32/80; HISTIOCYTIC SARCOMA 3/50 2/50 7/50 4/50 7/50 4/80
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LYMPHOMA 4/50 2/50 4/50 6/50 2/50 51/73, STOP STUDY 8/50 22/50 8/50 33/50; HISTIOCYTIC SARCOMA 0/50 0/50 4/50 5/50 7/50 4/73, STOP STUDY 5/50 2/50 7/50 2/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Intestines (Small)
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/50 1/50 1/50 1/50 2/50 0/73
|
May Have Been Related
|
Yes
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/49 0/49 0/48 0/50 2/50 0/80
|
May Have Been Related
|
Yes
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 0/50 3/48 1/49 0/73, STOP STUDY 4/48 1/50 3/49 1/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 15/49 14/49 15/50 19/50 16/50 2/80
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 21/50 23/50 30/50 25/48 33/48 5/72, STOP STUDY 27/49 19/49 19/50 11/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 4/50 15/50 19/50 24/50 25/50 22/78
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 21/50 23/50 19/50 31/49 35/50 3/73, STOP STUDY 36/50 28/50 32/50 17/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOACANTHOMA, ADENOCARCINOMA, OR MALIGNANT MIXED TUMOR 0/50 2/50 4/50 12/50 15/50 16/80
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Ovary
|
Clear Evidence |
Clear Evidence |
BENIGN OR MALIGNANT GRANULOSA CELL TUMOR 1/49 0/49 1/48 9/50 8/50 6/79; ADENOMA OR BENIGN MIXED TUMOR 2/49 4/49 1/48 4/50 6/50 2/79
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Preputial Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/50 0/50 0/50 0/50 5/50 0/73, STOP STUDY 1/50 4/50 4/50 3/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Subcutaneous Tissue
|
Clear Evidence |
Equivocal Evidence |
NEUROFIBROSARCOMA OR SARCOMA 1/50 2/50 3/50 5/50 3/50 3/80
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Vascular System (Heart)
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/50 0/50 0/50 1/49 21/50 23/80
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Vascular System (Heart)
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/50 0/49 1/50 5/48 20/48 4/73, STOP STUDY 15/50 7/50 33/50 13/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Zymbal Gland
|
Clear Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 0/50 0/50 0/50 0/50 0/50 2/80
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Zymbal Gland
|
Clear Evidence |
Equivocal Evidence |
(STOP STUDY) CARCINOMA 1/50 0/50 2/50 2/50
|
May Have Been Related
|
No
|
TR-319
|
106-46-7 |
1,4-Dichlorobenzene (p-dichlorobenzene) |
Mice |
B6C3F1 |
Male |
Gavage |
Adrenal Gland Medulla
|
Clear Evidence |
Equivocal Evidence |
PHEOCHROMOCYTOMA 0/47 2/48 4/49
|
May Have Been Related
|
Yes
|
TR-319
|
106-46-7 |
1,4-Dichlorobenzene (p-dichlorobenzene) |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 1/50 3/50 7/50
|
Neoplastic Lesions
|
No
|
TR-319
|
106-46-7 |
1,4-Dichlorobenzene (p-dichlorobenzene) |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 10/50 6/48 21/50; CARCINOMA 5/50 5/48 19/50
|
Neoplastic Lesions
|
No
|
TR-319
|
106-46-7 |
1,4-Dichlorobenzene (p-dichlorobenzene) |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/50 13/49 16/50; CARCINOMA 14/50 11/49 32/50
|
Neoplastic Lesions
|
No
|
TR-339
|
99-57-0 |
2-Amino-4-nitrophenol |
Mice |
B6C3F1 |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-339
|
99-57-0 |
2-Amino-4-nitrophenol |
Mice |
B6C3F1 |
Male |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-339
|
99-57-0 |
2-Amino-4-nitrophenol |
Rats |
F344/N |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
Yes
|
TR-339
|
99-57-0 |
2-Amino-4-nitrophenol |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 1/48 3/50
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/51 1/53 10/52
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/51 0/53 1/51 5/55 0/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/52 1/50 5/51 3/50
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 3/51 2/50 2/49 OR SQUAMOUS CELL CARCINOMA 0/50 0/51 1/50 2/49 COMBINED 0/50 3/51 3/50 4/49
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/51 0/53 0/51 1/55 5/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/52 6/50 8/51 15/50 OR CARCINOMA 1/52 6/50 5/51 7/50 COMBINED 3/52 12/50 13/51 19/50
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 3/50 6/51 12/50 18/49 OR CARCINOMA 1/50 1/51 4/50 4/49 COMBINED 4/50 7/51 16/50 22/49
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
MONONUCLEAR CELL LEUKEMIA 27/51 29/53 40/51 34/55 25/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 0/51 0/53 3/51 4/55 11/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Intestines (Small)
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 0/51 0/53 0/51 2/53 5/59
|
Neoplastic Lesions
|
Yes
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/51 0/53 1/51 3/55 1/59
|
May Have Been Related
|
Yes
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/51 3/50 2/49
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 3/52 3/50 9/51 17/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/52 2/50 6/51 5/50 COMBINED 5/52 5/50 15/51 19/50
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 12/50 4/51 12/50 21/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 3/50 7/51 8/50 11/49 COMBINED 15/50 11/51 16/50 25/49
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/51 0/53 3/51 1/55 4/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/51 1/53 0/51 3/55 3/60 COMBINED 1/51 1/53 3/51 4/55 7/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Mammary Gland
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/52 0/50 1/51 2/50
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 25/50 45/51 46/53 45/52
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 0/51 4/53 6/51 6/55 5/60 OR ADENOMA 0/51 0/53 1/51 1/55 0/60 COMBINED 0/51 4/53 7/51 7/55 5/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
MESOTHELIOMA 0/51 3/53 8/51 9/55 26/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/50 2/51 4/53 5/52 OR SQUAMOUS CELL CARCINOMA 0/50 1/51 1/53 1/52 COMBINED 2/50 3/51 5/53 6/52
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/51 4/53 8/51 10/55 12/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 1/51 0/55 2/60 COMBINED 0/51 4/53 9/51 10/55 13/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Pancreas Acinar Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 1/51 2/53 4/51 3/53 3/59
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Seminal Vesicle
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/51 0/53 0/51 0/55 1/59 OR CARCINOMA 0/51 0/53 0/51 0/55 1/59 COMBINED 0/51 0/53 0/51 0/55 2/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/51 0/53 2/51 5/55 11/60 OR KERATOACANTHOMA 3/51 5/53 11/51 16/55 10/60 OR TRICHOEPITHELIOMA 0/51 0/53 0/51 1/55 1/60 OR BASAL CELL ADENOMA 0/51 1/53 0/51 3/55 6/60 OR BASAL CELL CARCINOMA 0/51 0/53 2/51 2/55 0/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 0/51 0/55 1/60 COMBINED 4/51 6/53 14/51 24/55 21/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
SARCOMA 0/52 1/50 4/51 11/50
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
FIBROMA 2/51 8/53 11/51 15/55 7/60 OR FIBROSARCOMA 0/51 1/53 0/51 0/55 1/60 OR SARCOMA 0/51 0/53 2/51 3/55 2/60 COMBINED 2/51 9/53 13/51 16/55 10/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/51 2/53 3/52 OR CARCINOMA 0/50 0/51 0/53 1/52 COMBINED 0/50 0/51 2/53 4/52
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/51 1/53 2/51 2/55 7/59 OR CARCINOMA 0/51 1/53 4/51 1/55 2/59 COMBINED 0/51 2/53 6/51 3/55 9/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Urinary Bladder
|
Clear Evidence |
Clear Evidence |
TRANSITIONAL CELL PAPILLOMA 0/51 0/53 1/51 2/55 1/59 OR TRANSITIONAL CELL CARCINOMA 0/51 0/53 0/51 1/55 1/59 COMBINED 0/51 0/53 1/51 3/55 2/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Vascular System (Unspecified)
|
Clear Evidence |
Equivocal Evidence |
HEMANGIOMA AND HEMANGIOSARCOMA 1/52 2/50 0/51 5/50
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/51 0/53 1/51 3/55 2/60 OR CARCINOMA 2/51 1/53 3/51 2/55 15/60 COMBINED 2/51 1/53 4/51 5/55 15/60
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 3/50 OR ADENOCARCINOMA 0/50 0/50 3/50 COMBINED 0/50 1/50 6/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 9/50 38/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 19/50 33/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Female |
Topical Application |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 12/49 17/50 OR SQUAMOUS CELL CARCINOMA 0/50 7/47 6/50 COMBINED 0/50 18/49 19/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Male |
Topical Application |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 12/50 20/50 OR SQUAMOUS CELL CARCINOMA 0/50 2/50 1/49 COMBINED 0/50 14/50 21/49
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 3/50 23/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 17/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/50 3/50 4/49; ADENOMATOUS POLYP 0/50 12/50 37/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/50 8/50 11/50; ADENOMATOUS POLYP 1/50 13/50 29/50
|
Neoplastic Lesions
|
Yes
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 4/50
|
Neoplastic Lesions
|
Yes
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Male |
Topical Application |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 2/50 9/50 OR CARCINOMA 0/50 0/50 3/50 COMBINED 1/50 2/50 11/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULES 0/50 10/50 11/50 OR CARCINOMA 0/50 2/50 6/50 COMBINED 0/50 11/50 14/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULES 0/49 3/50 2/50 OR CARCINOMA 0/49 1/50 3/50 COMBINED 0/49 4/50 5/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Female |
Topical Application |
Lung
|
Clear Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 3/50 4/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 0/50 0/50 COMBINED 1/50 3/50 4/50
|
May Have Been Related
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Male |
Topical Application |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 1/50 6/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/50 0/50 5/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
0/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 44/50 49/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 48/50 48/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 27/50 41/50 OR SQUAMOUS CELL CARCINOMA 0/50 15/50 27/50 COMBINED 0/50 39/50 49/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 40/50 33/50 OR SQUAMOUS CELL CARCINOMA 0/50 16/50 25/50 COMBINED 0/50 47/50 48/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Female |
Topical Application |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 1/50 6/50; SEBACEOUS GLAND ADENOMA 0/50 3/50 2/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Male |
Topical Application |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 3/50 9/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 2/50 COMBINED 0/50 3/50 11/50; SEBACEOUS GLAND ADENOMA 0/50 1/50 8/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 2/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 3/50; BASAL CELL NEOPLASMS, SEBACEOUS GLAND ADENOMA OR KERATOACANTHOMA 0/50 3/50 18/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 3/50 0/50 OR SQUAMOUS CELL CARCINOMA 0/50 5/50 8/50 COMBINED 1/50 8/50 8/50; BASAL CELL NEOPLASMS, SEBACEOUS GLAND ADENOMA, OR KERATOACANTHOMA 0/50 20/50 31/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Vascular System (Spleen)
|
Clear Evidence |
Clear Evidence |
HEMANGIOMA 0/50 0/50 3/50 OR HEMANGIOSARCOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 7/50 3/50 OR ADENOCARCINOMA 1/50 2/50 19/50 COMBINED 1/50 9/50 22/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 7/50 OR ADENOCARCINOMA 0/50 8/50 29/50 COMBINED 0/50 9/50 35/50
|
Neoplastic Lesions
|
Yes
|
TR-401
|
137-09-7 |
2,4-Diaminophenol dihydrochloride |
Mice |
B6C3F1 |
Male |
Gavage |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 0/48 3/50
|
Neoplastic Lesions
|
No
|
TR-423
|
119-84-6 |
3,4-Dihydrocoumarin |
Mice |
B6C3F1 |
Male |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-423
|
119-84-6 |
3,4-Dihydrocoumarin |
Rats |
F344/N |
Male |
Gavage |
Kidney Transitional Cell
|
Some Evidence |
Equivocal Evidence |
CARCINOMA 0/50 0/48 0/47 2/50
|
May Have Been Related
|
Yes
|
TR-423
|
119-84-6 |
3,4-Dihydrocoumarin |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 1/48 0/47 2/50, STEP SECTIONS 1/50 0/48 3/47 5/50
|
Neoplastic Lesions
|
No
|
TR-423
|
119-84-6 |
3,4-Dihydrocoumarin |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 10/51 20/50 22/50 20/52 OR CARCINOMA 3/51 2/50 4/50 6/52 COMBINED 13/51 21/50 25/50 24/52
|
Neoplastic Lesions
|
No
|
TR-359
|
298-81-7 |
8-Methoxypsoralen |
Rats |
F344/N |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
Yes
|
TR-359
|
298-81-7 |
8-Methoxypsoralen |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 11/50 8/49 OR ADENOCARCINOMA 0/50 1/50 3/49
|
Neoplastic Lesions
|
No
|
TR-359
|
298-81-7 |
8-Methoxypsoralen |
Rats |
F344/N |
Male |
Gavage |
Lung
|
Clear Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 4/50 9/50 9/49
|
May Have Been Related
|
No
|
TR-359
|
298-81-7 |
8-Methoxypsoralen |
Rats |
F344/N |
Male |
Gavage |
Subcutaneous Tissue
|
Clear Evidence |
Equivocal Evidence |
FIBROMA 1/50 5/50 7/49
|
May Have Been Related
|
No
|
TR-359
|
298-81-7 |
8-Methoxypsoralen |
Rats |
F344/N |
Male |
Gavage |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 1/50 7/50 4/49
|
Neoplastic Lesions
|
No
|
TR-369
|
98-85-1 |
alpha-Methylbenzyl alcohol |
Mice |
B6C3F1 |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-369
|
98-85-1 |
alpha-Methylbenzyl alcohol |
Mice |
B6C3F1 |
Male |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
Yes
|
TR-369
|
98-85-1 |
alpha-Methylbenzyl alcohol |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 1/50 5/50 OR ADENOCARCINOMA 0/50 1/50 0/50 COMBINED 0/50 2/50 5/50
|
Neoplastic Lesions
|
No
|
TR-543
|
98-83-9 |
alpha-Methylstyrene |
Rats |
F344/N |
Male |
Inhalation |
Hematopoietic System
|
Some Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 26/50 32/50 29/50 38/50
|
May Have Been Related
|
Yes
|
TR-543
|
98-83-9 |
alpha-Methylstyrene |
Rats |
F344/N |
Male |
Inhalation |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOMA (STANDARD EVALUATION) 0/50 0/50 1/50 0/50 (STANDARD AND EXTENDED EVALUATIONS COMBINED) 1/50 2/50 2/50 5/50 ADENOMA OR CARCINOMA (STANDARD EVALUATION) 0/50 0/50 2/50 2/50 (STANDARD AND EXTENDED EVALUATIONS COMBINED) 1/50 2/50 3/50 7/50
|
Neoplastic Lesions
|
No
|
TR-543
|
98-83-9 |
alpha-Methylstyrene |
Mice |
B6C3F1/N |
Male |
Inhalation |
Liver
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 28/50 36/50 33/50 37/50
|
May Have Been Related
|
No
|
TR-543
|
98-83-9 |
alpha-Methylstyrene |
Mice |
B6C3F1/N |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 10/50 20/50 21/50 23/50 CARCINOMA 3/50 9/50 6/50 18/50 ADENOMA OR CARCINOMA 13/50 26/50 24/50 33/50
|
Neoplastic Lesions
|
No
|
TR-494
|
84-65-1 |
Anthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Transitional Cell
|
Some Evidence |
Some Evidence |
PAPILLOMA 0/50 0/50 2/50 0/50 1/50
|
Neoplastic Lesions
|
Yes
|
TR-494
|
84-65-1 |
Anthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 4/50 9/50 7/50 12/49; ADENOMA OR CARCINOMA 0/50 6/50 9/50 8/50 14/49
|
Neoplastic Lesions
|
Yes
|
TR-494
|
84-65-1 |
Anthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOMA 1/50 3/50 9/50 5/50 3/50
|
Neoplastic Lesions
|
No
|
TR-494
|
84-65-1 |
Anthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Some Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 1/50 3/50 4/50 5/50 3/50
|
May Have Been Related
|
No
|
TR-494
|
84-65-1 |
Anthraquinone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 6/49 28/50 27/50 40/49 OR CARCINOMA 2/49 3/50 8/50 8/49 COMBINED 6/49 30/50 30/50 41/49
|
Neoplastic Lesions
|
No
|
TR-494
|
84-65-1 |
Anthraquinone |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 21/50 32/50 38/50 41/49 OR CARCINOMA 8/50 13/50 17/50 21/49 OR HEPATOBLASTOMA 1/50 6/50 11/50 37/49 COMBINED 26/50 35/50 43/50 48/49
|
Neoplastic Lesions
|
No
|
TR-494
|
84-65-1 |
Anthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 6/50 4/50 3/50
|
Neoplastic Lesions
|
No
|
TR-494
|
84-65-1 |
Anthraquinone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 1/45 1/48 2/48 2/48 OR CARCINOMA 0/45 0/48 0/48 2/48 COMBINED 1/45 1/48 2/48 4/48
|
May Have Been Related
|
No
|
TR-494
|
84-65-1 |
Anthraquinone |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/50 0/50 2/49 2/46
|
May Have Been Related
|
No
|
TR-494
|
84-65-1 |
Anthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Urinary Bladder
|
Clear Evidence |
Clear Evidence |
TRANSITIONAL EPITHELIAL PAPILLOMA OR CARCINOMA 0/49 0/49 0/49 1/50 2/49
|
Neoplastic Lesions
|
No
|
TR-494
|
84-65-1 |
Anthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Urinary Bladder
|
Some Evidence |
Some Evidence |
TRANSITIONAL EPITHELIAL PAPILLOMA 0/50 1/50 3/50 7/50 3/49
|
Neoplastic Lesions
|
No
|
TR-370
|
271-89-6 |
Benzofuran |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/50 8/50 5/50 OR SQUAMOUS CELL CARCINOMA 0/50 1/50 1/50 COMBINED 2/50 9/50 5/50
|
Neoplastic Lesions
|
No
|
TR-370
|
271-89-6 |
Benzofuran |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/49 7/39 10/48 OR SQUAMOUS CELL CARCINOMA 0/49 4/39 3/48 COMBINED 2/49 11/39 13/48
|
Neoplastic Lesions
|
Yes
|
TR-370
|
271-89-6 |
Benzofuran |
Rats |
F344/N |
Female |
Gavage |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOCARCINOMA 0/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-370
|
271-89-6 |
Benzofuran |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 22/48 21/47; HEPATOBLASTOMA 0/50 1/48 2/47; ADENOMA, HEPATOBLASTOMA, OR CARCINOMA 3/50 3/48 1/47 COMBINED 4/50 25/48 22/47
|
Neoplastic Lesions
|
No
|
TR-370
|
271-89-6 |
Benzofuran |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 4/49 24/39 34/48; HEPATOBLASTOMA 0/49 3/39 18/48; ADENOMA, HEPATOBLASTOMA, OR CARCINOMA 9/49 8/39 9/48 COMBINED 12/49 31/39 40/48
|
Neoplastic Lesions
|
No
|
TR-370
|
271-89-6 |
Benzofuran |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 5/48 13/47 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 4/48 3/47 COMBINED 2/50 9/48 14/47
|
Neoplastic Lesions
|
No
|
TR-370
|
271-89-6 |
Benzofuran |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 4/49 7/39 15/48 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 7/49 3/39 5/48 COMBINED 10/49 9/39 19/48
|
Neoplastic Lesions
|
No
|
TR-533
|
119-61-9 |
Benzophenone |
Rats |
F344/N |
Male |
Dosed-Feed |
Hematopoietic System
|
Some Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 27/50 41/50 39/50 24/50
|
May Have Been Related
|
No
|
TR-533
|
119-61-9 |
Benzophenone |
Rats |
F344/N |
Female |
Dosed-Feed |
Hematopoietic System
|
Equivocal Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 19/50 25/50 30/50 29/50; HISTIOCYTIC SARCOMA 0/50 0/50 1/50 2/50
|
Neoplastic Lesions
|
No
|
TR-533
|
119-61-9 |
Benzophenone |
Mice |
B6C3F1/N |
Female |
Dosed-Feed |
Hematopoietic System
|
Some Evidence |
Some Evidence |
HISTIOCYTIC SARCOMA: 0/50 0/50 5/50 3/50
|
Neoplastic Lesions
|
Yes
|
TR-533
|
119-61-9 |
Benzophenone |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOMA (STANDARD EVALUATION) 1/50 1/50 2/50 4/50 (STANDARD AND EXTENDED EVALUATIONS COMBINED) 2/50 2/50 7/50 8/50
|
Neoplastic Lesions
|
No
|
TR-533
|
119-61-9 |
Benzophenone |
Mice |
B6C3F1/N |
Female |
Dosed-Feed |
Liver
|
Some Evidence |
Equivocal Evidence |
ADENOMA 5/50 4/50 10/50 8/50
|
May Have Been Related
|
No
|
TR-533
|
119-61-9 |
Benzophenone |
Mice |
B6C3F1/N |
Male |
Dosed-Feed |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 11/50 15/50 23/50 23/50 ADENOMA, CARCINOMA, OR HEPATOBLASTOMA 18/50 20/50 25/50 29/50
|
Neoplastic Lesions
|
No
|
TR-557
|
123-35-3 |
beta-Myrcene |
Rats |
F344/N |
Female |
Gavage |
Kidney Tubular Cell
|
Equivocal Evidence |
Equivocal Evidence |
Adenoma (standard evaluation) 0/50 1/50 0/50 2/50 extended evaluation 0/50 1/50 1/50 2/50 standard and extended evaluations 0/50 2/50 1/50 3/50
|
May Have Been Related
|
Yes
|
TR-557
|
123-35-3 |
beta-Myrcene |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
Adenoma (standard evaluation) 0/50 4/50 8/50 (standard and extended evaluations) 0/50 12/50 13/50 adenoma or carcinoma (standard evaluation) 0/50 7/50 9/50 (standard and extended evaluations) 0/50 14/50 13/50
|
Neoplastic Lesions
|
No
|
TR-557
|
123-35-3 |
beta-Myrcene |
Mice |
B6C3F1/N |
Female |
Gavage |
Liver
|
Equivocal Evidence |
Equivocal Evidence |
Adenoma 6/50 13/50 6/50 carcinoma 1/50 7/50 2/50 adenoma or carcinoma 7/50 18/50 8/50
|
May Have Been Related
|
No
|
TR-557
|
123-35-3 |
beta-Myrcene |
Mice |
B6C3F1/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
Adenoma 26/50 41/50 43/50 carcinoma 14/50 20/50 28/50 adenoma or carcinoma 33/50 44/50 48/50 hepatoblastoma 4/50 6/50 11/50 adenoma, carcinoma, or hepatoblastoma 34/50 45/50 48/50
|
Neoplastic Lesions
|
No
|
TR-321
|
75-27-4 |
Bromodichloromethane |
Rats |
F344/N |
Female |
Gavage |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP 0/46 0/50 7/47; ADENOCARCINOMA 0/46 0/50 6/47
|
Neoplastic Lesions
|
No
|
TR-321
|
75-27-4 |
Bromodichloromethane |
Rats |
F344/N |
Male |
Gavage |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP 0/50 3/50 33/50; ADENOCARCINOMA 0/50 11/50 38/50
|
Neoplastic Lesions
|
Yes
|
TR-321
|
75-27-4 |
Bromodichloromethane |
Mice |
B6C3F1 |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/49 2/50 6/50; ADENOCARCINOMA 0/49 0/50 4/50; COMBINED 1/49 2/50 9/50
|
Neoplastic Lesions
|
Yes
|
TR-321
|
75-27-4 |
Bromodichloromethane |
Rats |
F344/N |
Female |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 6/50; ADENOCARCINOMA 0/50 0/50 9/50; COMBINED 0/50 1/50 15/50
|
Neoplastic Lesions
|
Yes
|
TR-321
|
75-27-4 |
Bromodichloromethane |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 3/50; ADENOCARCINOMA 0/50 0/50 10/50; COMBINED 0/50, 1/50, 13/50
|
Neoplastic Lesions
|
No
|
TR-321
|
75-27-4 |
Bromodichloromethane |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 13/48 23/50; CARCINOMA 2/50 5/48 10/50
|
Neoplastic Lesions
|
No
|
TR-430
|
28407-37-6 |
C.I. Direct Blue 218 |
Rats |
F344/N |
Male |
Dosed-Feed |
Forestomach
|
Some Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 2/50 1/50; SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 0/50
|
May Have Been Related
|
No
|
TR-430
|
28407-37-6 |
C.I. Direct Blue 218 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Intestines (Small)
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 1/50 0/50 0/50 3/50
|
May Have Been Related
|
Yes
|
TR-430
|
28407-37-6 |
C.I. Direct Blue 218 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/50 2/50 1/50 1/50 OR CARCINOMA 0/50 1/50 0/50 0/50 COMBINED 0/50 3/50 1/50 1/50
|
May Have Been Related
|
No
|
TR-430
|
28407-37-6 |
C.I. Direct Blue 218 |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 7/49 12/50 17/49 41/49; CARCINOMA 5/49 5/50 6/49 12/49
|
Neoplastic Lesions
|
No
|
TR-430
|
28407-37-6 |
C.I. Direct Blue 218 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 16/50 19/50 17/50 40/50; CARCINOMA 7/50 3/50 8/50 17/50
|
Neoplastic Lesions
|
No
|
TR-430
|
28407-37-6 |
C.I. Direct Blue 218 |
Rats |
F344/N |
Male |
Dosed-Feed |
Oral Cavity
|
Some Evidence |
Some Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 0/50 5/51; SQUAMOUS CELL CARCINOMA 0/50 0/50 0/50 1/51; BASOSQUAMOUS TUMOR BENIGN 0/50 0/50 0/50 1/51
|
Neoplastic Lesions
|
No
|
TR-407
|
2425-85-6 |
C.I. Pigment Red 3 |
Rats |
F344/N |
Male |
Dosed-Feed |
Adrenal Gland Medulla
|
Some Evidence |
Some Evidence |
PHEOCHROMOCYTOMA 24/50 32/50 37/50 36/50
|
Neoplastic Lesions
|
Yes
|
TR-407
|
2425-85-6 |
C.I. Pigment Red 3 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 0/50 0/50 6/50
|
Neoplastic Lesions
|
No
|
TR-407
|
2425-85-6 |
C.I. Pigment Red 3 |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 0/50 1/50 10/50
|
Neoplastic Lesions
|
No
|
TR-407
|
2425-85-6 |
C.I. Pigment Red 3 |
Rats |
F344/N |
Male |
Dosed-Feed |
Skin
|
Some Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 4/50 2/50 6/50
|
May Have Been Related
|
No
|
TR-407
|
2425-85-6 |
C.I. Pigment Red 3 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 0/49 1/50 5/50
|
Neoplastic Lesions
|
No
|
TR-407
|
2425-85-6 |
C.I. Pigment Red 3 |
Rats |
F344/N |
Male |
Dosed-Feed |
Zymbal Gland
|
Some Evidence |
Equivocal Evidence |
CARCINOMA 0/50 0/50 2/50 3/50
|
May Have Been Related
|
No
|
TR-308
|
108171-26-2 |
Chlorinated paraffins: C12, 60% chlorine |
Rats |
F344/N |
Male |
Gavage |
Hematopoietic System
|
Clear Evidence |
Equivocal Evidence |
LEUKEMIA 7/50 12/50 14/50
|
May Have Been Related
|
Yes
|
TR-308
|
108171-26-2 |
Chlorinated paraffins: C12, 60% chlorine |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 7/50 3/49 ADENOCARCINOMA 0/50 2/50 0/49 COMBINED 0/50 9/50 3/49
|
Neoplastic Lesions
|
No
|
TR-308
|
108171-26-2 |
Chlorinated paraffins: C12, 60% chlorine |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 18/50 22/50 OR CARCINOMA 3/50 4/50 9/50 COMBINED 3/50 22/50 28/50
|
Neoplastic Lesions
|
No
|
TR-308
|
108171-26-2 |
Chlorinated paraffins: C12, 60% chlorine |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 11/50 20/50 29/50 OR CARCINOMA 11/50 15/50 17/50 COMBINED 2/50 34/50 38/50
|
Neoplastic Lesions
|
No
|
TR-308
|
108171-26-2 |
Chlorinated paraffins: C12, 60% chlorine |
Rats |
F344/N |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/50 4/50 7/50; CARCINOMA 0/50 1/50 1/50
|
Neoplastic Lesions
|
No
|
TR-308
|
108171-26-2 |
Chlorinated paraffins: C12, 60% chlorine |
Rats |
F344/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/50 10/50 16/48; CARCINOMA 0/50 3/50 2/48
|
Neoplastic Lesions
|
No
|
TR-308
|
108171-26-2 |
Chlorinated paraffins: C12, 60% chlorine |
Mice |
B6C3F1 |
Female |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 8/50 12/49 18/49 OR CARCINOMA 0/50 0/49 2/49 COMBINED 8/50 12/49 15/49
|
Neoplastic Lesions
|
No
|
TR-308
|
108171-26-2 |
Chlorinated paraffins: C12, 60% chlorine |
Rats |
F344/N |
Female |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 6/50 3/50 OR CARCINOMA 0/50 0/50 3/50 COMBINED 0/50 6/50 6/50
|
Neoplastic Lesions
|
No
|
TR-000 (67-66-3)
|
67-66-3 |
Chloroform |
Rats |
Osborne Mendel |
Female |
Gavage |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-000 (67-66-3)
|
67-66-3 |
Chloroform |
Rats |
Osborne Mendel |
Male |
Gavage |
Kidney Tubular Cell
|
Positive |
Positive |
ADENOMA OR ADENOCARCINOMA COMBINED
|
Neoplastic Lesions
|
No
|
TR-000 (67-66-3)
|
67-66-3 |
Chloroform |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-000 (67-66-3)
|
67-66-3 |
Chloroform |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
Squamous Cell Papilloma 0/50 0/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Male |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 0/50 2/50 4/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 3/50 3/50 8/50 OR CARCINOMA 1/50 2/50 0/50 1/50 COMBINED 2/50 5/50 3/50 9/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Male |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/50 5/50 8/50 10/50 OR CARCINOMA 0/50 0/50 2/50 2/50 COMBINED 2/50 5/50 10/50 12/50
|
Neoplastic Lesions
|
Yes
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
(SINGLE SECTIONS) ADENOMA 0/50 1/49 1/50 3/50 (SINGLE AND STEP SECTIONS) ADENOMA 0/50 2/49 3/50 9/50
|
Neoplastic Lesions
|
Yes
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
(SINGLE SECTIONS) ADENOMA 0/49 0/50 0/50 2/50 (SINGLE AND STEP SECTIONS) ADENOMA 0/49 0/50 0/50 4/50
|
Neoplastic Lesions
|
Yes
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
(SINGLE SECTIONS) ADENOMA 0/50 1/50 1/50 2/50 (SINGLE AND STEP SECTIONS) ADENOMA 1/50 7/50 6/50 7/50 OR CARCINOMA 0/50 2/50 0/50 1/50 COMBINED 1/50 9/50 6/50 8/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 17/50 19/49 11/50 16/50 OR CARCINOMA 4/50 11/49 14/50 19/50 COMBINED 20/50 26/49 20/50 30/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Lung
|
Clear Evidence |
Equivocal Evidence |
Alveolar/Bronchiolar Adenoma 1/49 0/50 0/50 3/50
|
May Have Been Related
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
Alveolar/Bronchiolar Adenoma 2/50 16/49 29/50 26/50 or Alveolar/Bronchiolar Carcinoma 2/50 14/49 16/50 28/50 Combined 4/50 28/49 34/50 42/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
Alveolar/Bronchiolar Adenoma 8/50 18/50 22/50 28/50 or Alveolar/Bronchiolar Carcinoma 6/50 12/50 23/50 28/50 Combined 13/50 28/50 36/50 43/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
Alveolar/Bronchiolar Adenoma 2/50 0/50 3/49 3/50 or Alveolar/Bronchiolar Carcinoma 0/50 2/50 1/49 4/50 Combined 2/50 2/50 4/49 6/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 3/50 4/50 7/50 12/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 24/49 32/50 36/50 36/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
SARCOMA 0/50 4/50 8/50 3/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/49 2/50 2/50 7/50 OR SQUAMOUS CELL CARCINOMA 0/49 1/50 3/50 4/50 COMBINED 1/49 3/50 5/50 11/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Male |
Inhalation |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 2/50 4/50 10/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 2/50 COMBINED 0/50 2/50 5/50 12/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
SARCOMA 0/50 11/50 11/50 18/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/49 1/50 0/50 3/50 OR CARCINOMA 0/49 0/50 1/50 2/50 COMBINED 1/49 1/50 1/50 5/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Male |
Inhalation |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 2/49 4/50 OR CARCINOMA 0/50 0/50 2/49 1/50 COMBINED 0/50 2/50 4/49 5/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Urinary Bladder
|
Clear Evidence |
Equivocal Evidence |
TRANSITIONAL EPITHELIUM CARCINOMA 0/49 0/50 0/50 2/50
|
May Have Been Related
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Male |
Inhalation |
Urinary Bladder
|
Clear Evidence |
Equivocal Evidence |
TRANSITIONAL EPITHELIUM PAPILLOMA 0/50 0/50 0/50 1/49 OR CARCINOMA 0/50 0/50 1/50 0/49
|
May Have Been Related
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Vascular System (Unspecified)
|
Clear Evidence |
Clear Evidence |
HEMANGIOMA 0/50 0/50 2/50 3/50 OR HEMANGIOSARCOMA 4/50 6/50 17/50 5/50 COMBINED 4/50 6/50 18/50 8/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Male |
Inhalation |
Vascular System (Unspecified)
|
Clear Evidence |
Clear Evidence |
HEMANGIOMA 0/50 1/50 2/50 2/50 OR HEMANGIOSARCOMA 3/50 13/50 22/50 19/50 COMBINED 3/50 14/50 23/50 21/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/50 0/50 0/50 3/50
|
Neoplastic Lesions
|
No
|
TR-041
|
1897-45-6 |
Chlorothalonil |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-041
|
1897-45-6 |
Chlorothalonil |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-041
|
1897-45-6 |
Chlorothalonil |
Rats |
Osborne Mendel |
Female |
Dosed-Feed |
Kidney Tubular Cell
|
Positive |
Positive |
ADENOMA
|
Neoplastic Lesions
|
Yes
|
TR-041
|
1897-45-6 |
Chlorothalonil |
Rats |
Osborne Mendel |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Positive |
Positive |
ADENOMA
|
Neoplastic Lesions
|
No
|
TR-196
|
87-29-6 |
Cinnamyl anthranilate |
Rats |
F344/N |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-196
|
87-29-6 |
Cinnamyl anthranilate |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Positive |
Positive |
ADENOMA OR ADENOCARCINOMA
|
Neoplastic Lesions
|
No
|
TR-196
|
87-29-6 |
Cinnamyl anthranilate |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(ADENOMA, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-196
|
87-29-6 |
Cinnamyl anthranilate |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(ADENOMA, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-196
|
87-29-6 |
Cinnamyl anthranilate |
Rats |
F344/N |
Male |
Dosed-Feed |
Pancreas Acinar Cell
|
Positive |
Positive |
ADENOMA OR CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-479
|
68603-42-9 |
Coconut oil acid diethanolamine condensate |
Rats |
F344/N |
Female |
Topical Application |
Kidney Tubular Cell
|
Equivocal Evidence |
Equivocal Evidence |
adenoma or carcinoma (standard evaluation 0/50, 2/50, 0/50; standard and extended evaluations combined 0/50, 4/50, 1/50)
|
May Have Been Related
|
Yes
|
TR-479
|
68603-42-9 |
Coconut oil acid diethanolamine condensate |
Mice |
B6C3F1 |
Male |
Topical Application |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
adenoma 1/50, 1/50, 7/50; renal tubule adenoma or carcinoma 1/50, 1/50, 9/50
|
Neoplastic Lesions
|
No
|
TR-479
|
68603-42-9 |
Coconut oil acid diethanolamine condensate |
Mice |
B6C3F1 |
Female |
Topical Application |
Liver
|
Clear Evidence |
Clear Evidence |
adenoma 32/50, 44/50, 43/50; hepatocellular carcinoma 3/50, 21/50, 32/50; hepatocellular adenoma, carcinoma, or hepatoblastoma 33/50, 46/50, 48/50
|
Neoplastic Lesions
|
No
|
TR-479
|
68603-42-9 |
Coconut oil acid diethanolamine condensate |
Mice |
B6C3F1 |
Male |
Topical Application |
Liver
|
Clear Evidence |
Clear Evidence |
adenoma 22/50, 35/50, 45/50; hepatoblastoma 1/50, 1/50, 10/50; hepatocellular adenoma, carcinoma, or hepatoblastoma 29/50, 39/50, 49/50
|
Neoplastic Lesions
|
No
|
TR-422
|
91-64-5 |
Coumarin |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 1/52 5/50 2/51 2/51
|
May Have Been Related
|
No
|
TR-422
|
91-64-5 |
Coumarin |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Some Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 2/50 8/50 2/50 0/51
|
May Have Been Related
|
No
|
TR-422
|
91-64-5 |
Coumarin |
Rats |
F344/N |
Female |
Gavage |
Kidney Tubular Cell
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 0/49 0/50 0/50 2/49, STEP SECTIONS 0/49 0/50 1/50 1/49
|
Neoplastic Lesions
|
Yes
|
TR-422
|
91-64-5 |
Coumarin |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOMA 1/49 2/50 2/51 1/50, STEP SECTIONS 0/49 4/50 5/51 4/50
|
Neoplastic Lesions
|
No
|
TR-422
|
91-64-5 |
Coumarin |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 8/50 26/49 29/51 12/50
|
Neoplastic Lesions
|
No
|
TR-422
|
91-64-5 |
Coumarin |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 2/51 5/49 7/49 20/51 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/51 0/49 0/49 7/51 COMBINED 2/51 5/49 7/49 27/51
|
Neoplastic Lesions
|
No
|
TR-422
|
91-64-5 |
Coumarin |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Some Evidence |
Some Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 14/50 8/50 14/50 24/51 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 1/50 2/50 1/51 COMBINED 14/50 9/50 15/50 25/51
|
Neoplastic Lesions
|
Yes
|
TR-542
|
98-82-8 |
Cumene |
Rats |
F344/N |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
renal tubule, adenoma or carcinoma (2/50, 5/50, 8/50, 7/50)
|
Neoplastic Lesions
|
No
|
TR-542
|
98-82-8 |
Cumene |
Mice |
B6C3F1/N |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
adenoma (18/50, 23/50, 27/50, 29/50); adenoma or carcinoma (25/50, 26/50, 29/50, 36/50)
|
Neoplastic Lesions
|
No
|
TR-542
|
98-82-8 |
Cumene |
Mice |
B6C3F1/N |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma (1/50, 26/50, 36/50, 38/50); alveolar/bronchiolar carcinoma (3/50, 16/50, 20/50, 34/50); alveolar/bronchiolar adenoma or carcinoma (4/50, 31/50, 42/50, 46/50)
|
Neoplastic Lesions
|
No
|
TR-542
|
98-82-8 |
Cumene |
Mice |
B6C3F1/N |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma (13/50, 31/50, 31/50, 29/50); alveolar/bronchiolar carcinoma (9/50, 19/50, 32/50, 33/50); alveolar/bronchiolar adenoma or carcinoma (19/50, 38/50, 42/50, 43/50)
|
Neoplastic Lesions
|
No
|
TR-542
|
98-82-8 |
Cumene |
Rats |
F344/N |
Male |
Inhalation |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
respiratory epithelium, adenoma (0/50, 7/50, 18/49, 10/50)
|
Neoplastic Lesions
|
No
|
TR-542
|
98-82-8 |
Cumene |
Rats |
F344/N |
Female |
Inhalation |
Nasal Cavity
|
Some Evidence |
Some Evidence |
respiratory epithelium, adenoma (0/50, 5/48, 4/50, 3/50)
|
Neoplastic Lesions
|
No
|
TR-542
|
98-82-8 |
Cumene |
Mice |
B6C3F1/N |
Male |
Inhalation |
Spleen
|
Clear Evidence |
Equivocal Evidence |
hemangioscaroma
|
May Have Been Related
|
No
|
TR-542
|
98-82-8 |
Cumene |
Rats |
F344/N |
Male |
Inhalation |
Testis
|
Clear Evidence |
Equivocal Evidence |
interstitial cell adenoma
|
May Have Been Related
|
No
|
TR-542
|
98-82-8 |
Cumene |
Mice |
B6C3F1/N |
Male |
Inhalation |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Equivocal Evidence |
adenoma
|
May Have Been Related
|
No
|
TR-347
|
5989-27-5 |
D-Limonene |
Mice |
B6C3F1 |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-347
|
5989-27-5 |
D-Limonene |
Mice |
B6C3F1 |
Male |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-347
|
5989-27-5 |
D-Limonene |
Rats |
F344/N |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
Yes
|
TR-347
|
5989-27-5 |
D-Limonene |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 4/50 8/50 OR ADENOCARCINOMA 0/50 4/50 3/50
|
Neoplastic Lesions
|
Yes
|
TR-463
|
8003-22-3 |
D&C Yellow No. 11 |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
(SINGLE SECTIONS) ADENOMA 0/50 0/51 0/51 2/54 OR CARCINOMA 0/50 0/51 1/51 0/54 COMBINED 0/50 0/51 1/51 2/54; (SINGLE AND STEP SECTIONS) ADENOMA 0/50 2/51 4/51 4/54 OR CARCINOMA 0/50 0/51 1/51 0/54 COMBINED 0/50 2/51 5/51 4/54
|
Neoplastic Lesions
|
No
|
TR-463
|
8003-22-3 |
D&C Yellow No. 11 |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 2/51 5/50 4/51 OR CARCINOMA 0/50 0/51 0/50 1/51 COMBINED 0/50 2/51 5/50 5/51
|
Neoplastic Lesions
|
No
|
TR-463
|
8003-22-3 |
D&C Yellow No. 11 |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 1/50 2/51 1/51 7/54
|
Neoplastic Lesions
|
No
|
TR-463
|
8003-22-3 |
D&C Yellow No. 11 |
Rats |
F344/N |
Female |
Dosed-Feed |
Oral Cavity
|
Some Evidence |
Equivocal Evidence |
SQUAMOUS CELL CARCINOMA 0/50 0/51 0/50 1/51
|
May Have Been Related
|
No
|
TR-463
|
8003-22-3 |
D&C Yellow No. 11 |
Rats |
F344/N |
Male |
Dosed-Feed |
Oral Cavity
|
Some Evidence |
Some Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 1/51 2/51 4/54 OR SQUAMOUS CELL CARCINOMA 0/50 1/51 1/51 1/54 COMBINED 1/50 2/51 3/51 5/54
|
Neoplastic Lesions
|
No
|
TR-513
|
91-17-8 |
Decalin |
Rats |
F344/N |
Female |
Inhalation |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-513
|
91-17-8 |
Decalin |
Rats |
F344/N |
Male |
Inhalation |
Adrenal Gland Medulla
|
Clear Evidence |
Clear Evidence |
BENIGN OR MALIGNANT PHEOCHROMOCYTOMA 8/49 9/49 13/49 16/49 8/20
|
Neoplastic Lesions
|
Yes
|
TR-513
|
91-17-8 |
Decalin |
Rats |
F344/N |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 2/50 6/49 9/50 5/20 ADENOMA OR CARCINOMA 1/50 3/50 7/49 12/50 6/20
|
Neoplastic Lesions
|
No
|
TR-513
|
91-17-8 |
Decalin |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 7/49 13/50 8/50 17/50 CARCINOMA 4/49 16/50 6/50 5/50 COMBINED 11/49 27/50 14/50 20/50
|
May Have Been Related
|
No
|
TR-513
|
91-17-8 |
Decalin |
Mice |
B6C3F1 |
Female |
Inhalation |
Uterus/Cervix
|
Equivocal Evidence |
Equivocal Evidence |
STROMAL POLYP 0/49 0/50 2/50 3/50 STROMAL POLYP OR STROMAL SARCOMA 0/49 0/50 2/50 4/50
|
May Have Been Related
|
Yes
|
TR-478
|
111-42-2 |
Diethanolamine |
Mice |
B6C3F1 |
Male |
Topical Application |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
(SINGLE SECTIONS) ADENOMA 1/50 4/50 6/50 6/50 COMBINED 3/50 5/50 6/50 8/50; (SINGLE AND STEP SECTIONS) ADENOMA 1/50 6/50 8/50 7/50 COMBINED 3/50 7/50 8/50 9/50
|
Neoplastic Lesions
|
No
|
TR-478
|
111-42-2 |
Diethanolamine |
Mice |
B6C3F1 |
Female |
Topical Application |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 32/50 50/50 48/50 48/50 OR CARCINOMA 5/50 19/50 38/50 42/50
|
Neoplastic Lesions
|
No
|
TR-478
|
111-42-2 |
Diethanolamine |
Mice |
B6C3F1 |
Male |
Topical Application |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 31/50 42/50 49/50 45/50, CARCINOMA 12/50 17/50 33/50 34/50 OR HEPATOBLASTOMA 0/50 2/50 8/50 5/50
|
Neoplastic Lesions
|
No
|
TR-323
|
756-79-6 |
Dimethyl methylphosphonate |
Mice |
B6C3F1 |
Male |
Gavage |
Unspecified
|
Inadequate Study |
|
Not applicable
|
Not applicable
|
No
|
TR-323
|
756-79-6 |
Dimethyl methylphosphonate |
Mice |
B6C3F1 |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-323
|
756-79-6 |
Dimethyl methylphosphonate |
Rats |
F344/N |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-323
|
756-79-6 |
Dimethyl methylphosphonate |
Rats |
F344/N |
Male |
Gavage |
Hematopoietic System
|
Some Evidence |
Equivocal Evidence |
LEUKEMIA 10/50 11/50 17/50
|
May Have Been Related
|
No
|
TR-323
|
756-79-6 |
Dimethyl methylphosphonate |
Rats |
F344/N |
Male |
Gavage |
Kidney Transitional Cell
|
Some Evidence |
Some Evidence |
PAPILLOMA 0/50 7/50 3/49
|
Neoplastic Lesions
|
Yes
|
TR-323
|
756-79-6 |
Dimethyl methylphosphonate |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOCARCINOMA 0/50 2/50 3/49
|
Neoplastic Lesions
|
Yes
|
TR-466
|
100-41-4 |
Ethylbenzene |
Rats |
F344/N |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
(SINGLE SECTIONS) ADENOMA 0/50 3/50 2/50 4/50 OR CARCINOMA 0/50 0/50 1/50 3/50 COMBINED 0/50 3/50 3/50 7/50; (SINGLE AND STEP SECTIONS) ADENOMA 3/50 5/50 7/50 20/50 OR CARCINOMA 0/50 0/50 1/50 3/50 COMBINED 3/50 5/50 8/50 21/50
|
Neoplastic Lesions
|
Yes
|
TR-466
|
100-41-4 |
Ethylbenzene |
Rats |
F344/N |
Female |
Inhalation |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
(SINGLE SECTIONS) ADENOMA 0/50 0/50 0/50 1/49 (SINGLE AND STEP SECTIONS) ADENOMA 0/50 0/50 1/50 8/49
|
Neoplastic Lesions
|
No
|
TR-466
|
100-41-4 |
Ethylbenzene |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 6/50 9/50 12/50 16/50 OR CARCINOMA 7/50 4/50 3/50 12/50 COMBINED 13/50 12/50 15/50 25/50
|
Neoplastic Lesions
|
No
|
TR-466
|
100-41-4 |
Ethylbenzene |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Some Evidence |
Some Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 5/50 9/50 10/50 16/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/50 1/50 5/50 3/50 COMBINED 7/50 10/50 15/50 19/50
|
Neoplastic Lesions
|
No
|
TR-466
|
100-41-4 |
Ethylbenzene |
Rats |
F344/N |
Male |
Inhalation |
Testis
|
Clear Evidence |
Clear Evidence |
ADENOMA 36/50 33/50 40/50 44/50
|
Neoplastic Lesions
|
No
|
TR-496
|
116355-83-0 |
Fumonisin B1 |
Rats |
F344/N |
Female |
Dosed-Feed |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
Yes
|
TR-496
|
116355-83-0 |
Fumonisin B1 |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
Adenoma 0/48 0/40 0/48 2/48 5/48 or Carcinoma 0/48 0/40 0/48 7/48 10/48 Combined 0/48 0/40 0/48 9/48 15/48
|
Neoplastic Lesions
|
No
|
TR-496
|
116355-83-0 |
Fumonisin B1 |
Mice |
MV |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
Adenoma 5/47 3/48 1/48 16/47 31/45 or Carcinoma 0/47 0/48 0/48 10/47 9/45 Combined 5/47 3/48 1/48 19/47 39/45
|
Neoplastic Lesions
|
No
|
TR-382
|
98-01-1 |
Furfural |
Rats |
F344/N |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-382
|
98-01-1 |
Furfural |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Some Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 0/50 1/50 6/50
|
May Have Been Related
|
Yes
|
TR-382
|
98-01-1 |
Furfural |
Mice |
B6C3F1 |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/50 0/50 1/49 1/50 OR CARCINOMA 0/50 1/50 0/49 0/50 COMBINED 0/50 1/50 1/49 1/50
|
May Have Been Related
|
No
|
TR-382
|
98-01-1 |
Furfural |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 9/50 13/50 11/49 19/50; CARCINOMA 7/50 12/50 6/49 21/50
|
Neoplastic Lesions
|
No
|
TR-382
|
98-01-1 |
Furfural |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 1/50 3/50 5/50 8/50
|
Neoplastic Lesions
|
No
|
TR-382
|
98-01-1 |
Furfural |
Rats |
F344/N |
Male |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
CHOLANGIOCARCINOMA 0/50 0/50 2/50
|
Neoplastic Lesions
|
No
|
TR-482
|
98-00-0 |
Furfuryl alcohol |
Rats |
F344/N |
Female |
Inhalation |
Kidney Tubular Cell
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA (SINGLE AND STEP SECTIONS) COMBINED 0/50 1/49 2/49 2/50
|
May Have Been Related
|
Yes
|
TR-482
|
98-00-0 |
Furfuryl alcohol |
Mice |
B6C3F1 |
Male |
Inhalation |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
(SINGLE SECTIONS) ADENOMA 0/50 0/49 049 2/50 OR CARCINOMA 0/50 0/49 0/49 2/50 COMBINED 0/50 0/49 0/49 4/50; (SINGLE AND STEP SECTIONS) ADENOMA 0/50 0/49 0/49 3/50 COMBINED 0/50 0/49 0/49 5/50
|
Neoplastic Lesions
|
No
|
TR-482
|
98-00-0 |
Furfuryl alcohol |
Rats |
F344/N |
Female |
Inhalation |
Nasal Cavity
|
Equivocal Evidence |
Equivocal Evidence |
RESPIRATORY EPITHELIUM ADENOMA 0/49 0/50 0/48 1/49; LATERAL WALL ADENOMA 0/49 0/50 1/48 0/49
|
May Have Been Related
|
No
|
TR-482
|
98-00-0 |
Furfuryl alcohol |
Rats |
F344/N |
Male |
Inhalation |
Nasal Cavity
|
Some Evidence |
Some Evidence |
ADENOMA, CARCINOMA, OR SQUAMOUS CELL CARCINOMA 0/50 1/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Brain
|
Clear Evidence |
Clear Evidence |
GLIOMA 0/50 4/50 4/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Brain
|
Clear Evidence |
Clear Evidence |
GLIOMA 0/50 5/50 6/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 3/50 7/50 7/50, ADENOCARCINOMA 0/50 1/50 0/50, OR CARCINOMA 2/50 1/50 5/50 COMBINED 5/50 9/50 12/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Epididymis
|
Clear Evidence |
Equivocal Evidence |
SARCOMA 0/50 0/50 2/50
|
May Have Been Related
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 2/50 9/50 OR SQUAMOUS CELL CARCINOMA 1/50 0/50 1/50 COMBINED 1/50 2/50 10/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 4/50 8/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 3/50 COMBINED 0/50 4/50 11/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 1/50 1/50 2/50 COMBINED 1/50 2/50 6/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Glandular Stomach
|
Clear Evidence |
Equivocal Evidence |
FIBROSARCOMA 0/50 0/50 2/50
|
May Have Been Related
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 4/50 10/50 16/50 OR ADENOCARCINOMA 0/50 1/50 1/50 COMBINED 4/50 11/50 17/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 7/50 10/50 16/50 OR ADENOCARCINOMA 1/50 2/50 7/50 COMBINED 8/50 12/50 22/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LEUKEMIA 13/50 14/50 20/50
|
Neoplastic Lesions
|
Yes
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 1/50 3/50 COMBINED 0/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 18/50 16/50 30/50 OR CARCINOMA 10/50 17/50 8/50 COMBINED 24/50 31/50 35/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 6/50 6/50 8/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 7/50 5/50 14/50 COMBINED 13/50 11/50 21/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 0/50, FIBROADENOMA 1/50 0/50 0/50, OR ADENOCARCINOMA 1/50 5/50 15/50 COMBINED 2/50 6/50 15/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 14/50 32/50 29/50; ADENOCARCINOMA 1/50 11/50 16/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 3/50 8/50 7/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
MESOTHELIOMA 3/50 34/50 39/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 3/50 6/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 1/50 3/50 7/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 1/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 2/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
SEBACEOUS GLAND ADENOMA 0/50 0/50 1/50, BASAL CELL CARCINOMA 0/50 4/50 2/50, OR SEBACEOUS GLAND ADENOCARCINOMA 0/50 0/50 1/50 COMBINED 0/50 5/50 4/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
SARCOMA 0/50 1/50 6/50 OR FIBROSARCOMA 0/50 2/50 3/50 COMBINED 0/50 3/50 9/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 0/49 OR CARCINOMA 0/50 0/50 3/49 COMBINED 0/50 1/50 3/49
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 2/50 OR CARCINOMA 1/50 2/50 5/50 COMBINED 1/50 4/50 6/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Urinary Bladder
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/50 1/50 1/50
|
May Have Been Related
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 3/50 2/50 COMBINED 0/50 3/50 3/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 1/50 3/50 6/50
|
Neoplastic Lesions
|
No
|
TR-361
|
67-72-1 |
Hexachloroethane |
Rats |
F344/N |
Male |
Gavage |
Adrenal Gland Medulla
|
Clear Evidence |
Equivocal Evidence |
PHEOCHROMOCYTOMA 15/50 28/45 21/49
|
May Have Been Related
|
Yes
|
TR-361
|
67-72-1 |
Hexachloroethane |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 2/50 3/50 OR CARCINOMA 0/50 0/50 3/50 COMBINED 1/50 2/50 7/50
|
Neoplastic Lesions
|
Yes
|
TR-361
|
67-72-1 |
Hexachloroethane |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/50 1/50
|
Neoplastic Lesions
|
No
|
TR-366
|
123-31-9 |
Hydroquinone |
Rats |
F344/N |
Female |
Gavage |
Hematopoietic System
|
Some Evidence |
Some Evidence |
Leukemia 9/55 15/55 22/55
|
Neoplastic Lesions
|
Yes
|
TR-366
|
123-31-9 |
Hydroquinone |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
Adenoma 0/55 4/55 8/55
|
Neoplastic Lesions
|
No
|
TR-366
|
123-31-9 |
Hydroquinone |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
Adenoma 2/55 15/55 12/55; adenoma or carcinoma (combined) 3/55 16/55 13/55
|
Neoplastic Lesions
|
No
|
TR-291
|
78-59-1 |
Isophorone |
Mice |
B6C3F1 |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-291
|
78-59-1 |
Isophorone |
Rats |
F344/N |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-291
|
78-59-1 |
Isophorone |
Mice |
B6C3F1 |
Male |
Gavage |
Hematopoietic System
|
Equivocal Evidence |
Equivocal Evidence |
LYMPHOMA 8/48 18/50 5/50
|
Neoplastic Lesions
|
Yes
|
TR-291
|
78-59-1 |
Isophorone |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 0/50 2/50 OR ADENOCARCINOMA 0/50 3/50 1/50
|
Neoplastic Lesions
|
No
|
TR-291
|
78-59-1 |
Isophorone |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 6/48 7/50 13/50 OR CARCINOMA 14/48 13/50 22/50 COMBINED 18/48 18/50 29/50
|
Neoplastic Lesions
|
No
|
TR-291
|
78-59-1 |
Isophorone |
Rats |
F344/N |
Male |
Gavage |
Preputial Gland
|
Some Evidence |
Some Evidence |
CARCINOMA 0/50 0/50 5/50
|
Neoplastic Lesions
|
No
|
TR-291
|
78-59-1 |
Isophorone |
Mice |
B6C3F1 |
Male |
Gavage |
Subcutaneous Tissue
|
Equivocal Evidence |
Equivocal Evidence |
FIBROMA 0/48 2/50 3/50; FIBROSARCOMA 3/48 4/50 10/50; NEUROFIBROSARCOMA 1/48 0/50 0/50; SARCOMA 0/48 0/50 1/50
|
Neoplastic Lesions
|
No
|
TR-486
|
78-79-5 |
Isoprene |
Rats |
F344/N |
Female |
Inhalation |
Brain
|
Some Evidence |
Equivocal Evidence |
ASTROCYTOMA 0/50 0/50 1/50 0/50, GLIOMA 0/50 0/50 0/50 1/50, MEDULOBLASTOMA 0/50 0/50 0/50 1/50, MENINGEAL GRANULAR CELL TUMOR 0/50 1/50 0/50 1/50, MENINGEAL SARCOMA 0/50 1/50 0/50 1/50
|
May Have Been Related
|
Yes
|
TR-486
|
78-79-5 |
Isoprene |
Rats |
F344/N |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
(SINGLE SECTION) ADENOMA 0/50 2/50 2/50 6/50 (SINGLE AND STEP SECTION) ADENOMA 2/50 4/50 8/50 15/50
|
Neoplastic Lesions
|
No
|
TR-486
|
78-79-5 |
Isoprene |
Rats |
F344/N |
Male |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 2/50 4/50 6/50 21/50 FIBROADENOMA OR CARCINOMA COMBINED 2/50 5/50 7/50 21/50
|
Neoplastic Lesions
|
No
|
TR-486
|
78-79-5 |
Isoprene |
Rats |
F344/N |
Female |
Inhalation |
Mammary Gland
|
Some Evidence |
Some Evidence |
FIBROADENOMA 19/50 35/50 32/50 32/50 MULTIPLE FIBROADENOMA 7/50 12/50 19/50 17/50
|
Neoplastic Lesions
|
No
|
TR-486
|
78-79-5 |
Isoprene |
Rats |
F344/N |
Male |
Inhalation |
Testis
|
Clear Evidence |
Clear Evidence |
ADENOMA 33/50 37/50 44/50 48/50
|
Neoplastic Lesions
|
No
|
TR-538
|
108-10-1 |
Methyl isobutyl ketone |
Rats |
F344/N |
Male |
Inhalation |
Hematopoietic System
|
Some Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 25/50 26/50 32/50 35/50
|
May Have Been Related
|
No
|
TR-538
|
108-10-1 |
Methyl isobutyl ketone |
Rats |
F344/N |
Female |
Inhalation |
Kidney Mesenchymal Cell
|
Equivocal Evidence |
Equivocal Evidence |
TUMOR MALIGNANT 0/50 0/50 0/50 2/50
|
Neoplastic Lesions
|
Yes
|
TR-538
|
108-10-1 |
Methyl isobutyl ketone |
Rats |
F344/N |
Male |
Inhalation |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOMA (STANDARD EVALUATION - 0/50 0/50 2/50 3/50; STANDARD AND EXTENDED EVAULATION COMBINED - 2/50 3/50 3/50 10/50); CARCINOMA (STANDARD EVALUATION - 0/50 1/50 0/50 2/50); ADENOMA OR CARCINOMA (COMBINED) (STANDARD EVAULATION - 0/50 1/50 2/50 4/50; STANDARD AND EXTENDED EVALUATION - 2/50 4/50 3/50 11/50)
|
Neoplastic Lesions
|
No
|
TR-538
|
108-10-1 |
Methyl isobutyl ketone |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 13/50 15/50 20/50 23/50 ADENOMA OR CARCINOMA (COMBINED) 17/50 17/50 22/50 27/50
|
Neoplastic Lesions
|
No
|
TR-538
|
108-10-1 |
Methyl isobutyl ketone |
Mice |
B6C3F1 |
Male |
Inhalation |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 17/50 25/50 23/50 34/50 ADENOMA OR CARCINOMA (COMBINED) 27/50 34/50 28/50 37/50
|
Neoplastic Lesions
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA OR CARCINOMA 0/50 0/50 1/50 3/50
|
May Have Been Related
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Mice |
B6C3F1 |
Male |
Gavage |
Glandular Stomach
|
Clear Evidence |
Clear Evidence |
MALIGNANT NEUROENDOCRINE TUMOR 0/49 0/48 0/49 2/50
|
Neoplastic Lesions
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Rats |
F344/N |
Female |
Gavage |
Glandular Stomach
|
Clear Evidence |
Clear Evidence |
BENIGN NEUROENDOCRINE TUMOR 0/50 0/50 13/50 9/50 5/50 OR MALIGNANT NEUROENDOCRINE TUMOR 0/50 1/50 12/50 26/50 36/50 COMBINED 0/50 1/50 25/50 34/50 41/50
|
Neoplastic Lesions
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Rats |
F344/N |
Male |
Gavage |
Glandular Stomach
|
Clear Evidence |
Clear Evidence |
BENIGN NEUROENDOCRINE TUMOR 1/50 0/50 0/50 3/50 2/50 OR MALIGNANT NEURENDOCRINE TUMOR 0/50 0/50 0/50 4/50 2/50 COMBINED 1/50 0/50 0/50 7/50 4/50
|
Neoplastic Lesions
|
Yes
|
TR-491
|
93-15-2 |
Methyleugenol |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA (STANDARD AND EXTENDED COMBINED) 4/50 6/50 17/50 13/50 20/50
|
Neoplastic Lesions
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 20/50 48/50 46/49 41/50 OR CARCINOMA 7/50 37/50 47/49 47/50 COMBINED 25/50 50/50 49/49 49/50; HEPATOBLASTOMA 0/50 6/50 11/49 15/50; HEPATOCHOLANGIOCARCINOMA 0/50 0/50 0/50 2/50
|
Neoplastic Lesions
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 26/49 43/50 38/50 39/50 CARCINOMA 10/49 20/50 19/50 9/50 COMBINED 31/49 47/50 46/50 40/50; HEPATOBLASTOMA 0/49 0/50 1/50 3/50
|
Neoplastic Lesions
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Rats |
F344/N |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 8/50 11/49 33/49 43/50 OR CARCINOMA 0/50 0/50 4/49 8/49 22/50 COMBINED 1/50 8/50 14/49 34/49 43/50; HEPATOCHOLANGIOMA 0/50 0/50 0/49 0/49 8/50 OR HEPATOCHOLANGIOCARCINOMA 0/50 0/50 0/49 3/49 9/50 COMBINED 0/50 0/50 0/49 3/49 17/50
|
Neoplastic Lesions
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Rats |
F344/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/50 12/50 23/50 38/50 32/50 OR CARCINOMA 2/50 3/50 14/50 25/50 36/50 COMBINED 7/50 14/50 28/50 43/50 45/50; HEPATOCHOLANGIOMA 0/50 0/50 0/50 1/50 6/50 OR HEPATOCHOLANGIOCARCINOMA 0/50 0/50 1/50 1/50 7/50 COMBINED 0/50 0/50 1/50 2/50 13/50
|
Neoplastic Lesions
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Rats |
F344/N |
Male |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 5/50 5/50 15/50 13/50 6/50
|
Neoplastic Lesions
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Rats |
F344/N |
Male |
Gavage |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
MESOTHELIOMA 1/50 3/50 5/50 12/50 5/50
|
Neoplastic Lesions
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Rats |
F344/N |
Male |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
FIBROMA 1/50 9/50 8/50 5/50 4/50 OR FIBROMA OR FIBROSARCOMA 1/50 12/50 8/50 8/50 4/50
|
Neoplastic Lesions
|
No
|
TR-266
|
150-68-5 |
Monuron |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-266
|
150-68-5 |
Monuron |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
Yes
|
TR-266
|
150-68-5 |
Monuron |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 7/50 OR ADENOCARCINOMA 0/50 1/50 8/50
|
Neoplastic Lesions
|
No
|
TR-266
|
150-68-5 |
Monuron |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 1/50 6/49 7/50 OR CARCINOMA 0/50 1/49 3/50 COMBINED 1/50 6/49 9/50
|
Neoplastic Lesions
|
Yes
|
TR-006
|
139-13-9 |
Nitrilotriacetic acid (NTA) |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Kidney Tubular Cell
|
Positive |
Positive |
ADENOCARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-006
|
139-13-9 |
Nitrilotriacetic acid (NTA) |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Positive |
Positive |
ADENOCARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-006
|
139-13-9 |
Nitrilotriacetic acid (NTA) |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Positive |
Positive |
ADENOMA OR ADENOCARCINOMA
|
Neoplastic Lesions
|
No
|
TR-006
|
139-13-9 |
Nitrilotriacetic acid (NTA) |
Rats |
F344/N |
Male |
Dosed-Feed |
Ureter
|
Positive |
Positive |
(ADENOMA OR PAPILLOMA)
|
Neoplastic Lesions
|
No
|
TR-006
|
139-13-9 |
Nitrilotriacetic acid (NTA) |
Rats |
F344/N |
Female |
Dosed-Feed |
Urinary Bladder
|
Positive |
Positive |
(TRANSITIONAL CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-006
|
18662-53-8 |
Nitrilotriacetic acid trisodium monohydrate |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-006
|
18662-53-8 |
Nitrilotriacetic acid trisodium monohydrate |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-006
|
18662-53-8 |
Nitrilotriacetic acid trisodium monohydrate |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Transitional Cell
|
Equivocal Evidence |
Equivocal |
PAPILLOMA
|
Neoplastic Lesions
|
No
|
TR-006
|
18662-53-8 |
Nitrilotriacetic acid trisodium monohydrate |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Transitional Cell
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-006
|
18662-53-8 |
Nitrilotriacetic acid trisodium monohydrate |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Equivocal Evidence |
Equivocal |
ADENOCARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-006
|
18662-53-8 |
Nitrilotriacetic acid trisodium monohydrate |
Rats |
F344/N |
Female |
Dosed-Feed |
Kidney Tubular Cell
|
Positive |
Positive |
ADENOMA OR ADENOCARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-006
|
18662-53-8 |
Nitrilotriacetic acid trisodium monohydrate |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Positive |
Positive |
ADENOCARCINOMA OR CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-006
|
18662-53-8 |
Nitrilotriacetic acid trisodium monohydrate |
Rats |
F344/N |
Female |
Dosed-Feed |
Ureter
|
Positive |
Positive |
(TRANSITIONAL CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-006
|
18662-53-8 |
Nitrilotriacetic acid trisodium monohydrate |
Rats |
F344/N |
Male |
Dosed-Feed |
Ureter
|
Positive |
Positive |
(TRANSITIONAL CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-006
|
18662-53-8 |
Nitrilotriacetic acid trisodium monohydrate |
Rats |
F344/N |
Female |
Dosed-Feed |
Urinary Bladder
|
Equivocal Evidence |
Equivocal |
(TRANSITIONAL CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-006
|
18662-53-8 |
Nitrilotriacetic acid trisodium monohydrate |
Rats |
F344/N |
Female |
Dosed-Feed |
Urinary Bladder
|
Positive |
Positive |
(TRANSITIONAL CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-341
|
67-20-9 |
Nitrofurantoin |
Rats |
F344/N |
Female |
Dosed-Feed |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-341
|
67-20-9 |
Nitrofurantoin |
Rats |
F344/N |
Male |
Dosed-Feed |
Bone
|
Some Evidence |
Equivocal Evidence |
OSTEOSARCOMA 0/50 1/50 2/50
|
May Have Been Related
|
Yes
|
TR-341
|
67-20-9 |
Nitrofurantoin |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 1/50 2/50 OR CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 1/50 3/50
|
Neoplastic Lesions
|
No
|
TR-341
|
67-20-9 |
Nitrofurantoin |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Ovary
|
Clear Evidence |
Clear Evidence |
TUBULAR CELL ADENOMA 0/50 0/50 5/50; BENIGN MIXED TUMORS 0/50 0/50 4/50; GRANULOSA CELL TUMOR 0/50 3/50 2/50
|
Neoplastic Lesions
|
No
|
TR-341
|
67-20-9 |
Nitrofurantoin |
Rats |
F344/N |
Male |
Dosed-Feed |
Subcutaneous Tissue
|
Some Evidence |
Equivocal Evidence |
FIBROMA 0/50 5/50 4/50; FIBROSARCOMA 1/50 2/50 1/50
|
May Have Been Related
|
No
|
TR-424
|
120-32-1 |
o-Benzyl-p-chlorophenol |
Rats |
F344/N |
Female |
Gavage |
Kidney Transitional Cell
|
Equivocal Evidence |
Equivocal Evidence |
CARCINOMA 0/50 0/50 1/51 1/50
|
Neoplastic Lesions
|
Yes
|
TR-424
|
120-32-1 |
o-Benzyl-p-chlorophenol |
Mice |
B6C3F1 |
Male |
Gavage |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 2/50 2/50 2/50 OR CARCINOMA 0/50 0/50 2/50 1/50 COMBINED 0/50 2/50 4/50 3/50; (STEP SECTIONS) ADENOMA 0/50 1/50 2/50 3/50 OR CARCINOMA 0/50 0/50 1/50 0/50 COMBINED 0/50 1/50 3/50 3/50
|
Neoplastic Lesions
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Female |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 0/50 1/50
|
May Have Been Related
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Male |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA O/50 0/50 1/50 1/50; SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 1/50
|
May Have Been Related
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Female |
Dosed-Feed |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
MONONUCLEAR CELL LEUKEMIA 14/50 11/50 14/50 26/50
|
Neoplastic Lesions
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Male |
Dosed-Feed |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
MONONUCLEAR CELL LEUKEMIA 26/50 25/50 42/50 34/50
|
Neoplastic Lesions
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Female |
Dosed-Feed |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
(STOP STUDY) ADENOMATOUS POLYP 0/60 8/60 18/60, CARCINOMA 0/60 0/60 2/60
|
Neoplastic Lesions
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Male |
Dosed-Feed |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
(STOP STUDY) ADENOMATOUS POLYP 0/60 26/60 30/60, CARCINOMA 0/60 0/60 5/60
|
Neoplastic Lesions
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Female |
Dosed-Feed |
Kidney Transitional Cell
|
Clear Evidence |
Clear Evidence |
(STOP STUDY) PAPILLOMA 0/60 0/60 1/60 OR CARCINOMA 0/60 0/60 1/60
|
Neoplastic Lesions
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Transitional Cell
|
Clear Evidence |
Clear Evidence |
PAPILLOMA (STOP STUDY) 0/60 0/60 4/60 OR CARCINOMA 0/60 1/60 8/60
|
Neoplastic Lesions
|
Yes
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/49 1/50 1/50 1/49 OR CARCINOMA 0/49 0/50 0/50 2/49
|
May Have Been Related
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 14/50 26/50 41/50 29/50; CARCINOMA 7/50 12/50 11/50 7/50; HEPATOBLASTOMA 0/50 3/50 17/50 9/50
|
Neoplastic Lesions
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 14/50 2/50 36/50 18/50
|
Neoplastic Lesions
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Female |
Dosed-Feed |
Urinary Bladder
|
Clear Evidence |
Clear Evidence |
(STOP STUDY) TRANSITIONAL CELL PAPILLOMA 0/58 2/59 1/60, TRANSITIONAL CELL CARCINOMA 0/58 28/59 48/60
|
Neoplastic Lesions
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Male |
Dosed-Feed |
Urinary Bladder
|
Clear Evidence |
Clear Evidence |
(STOP STUDY) TRANSITIONAL CELL PAPILLOMA 0/59 9/59 1/60, TRANSITIONAL CELL CARCINOMA 0/59 27/59 50/60, SQUAMOUS CELL PAPILLOMA 0/59 0/59 4/60, SQUAMOUS CELL CARCINOMA 0/59 0/59 6/60, SARCOMA 0/59 2/59 9/60
|
Neoplastic Lesions
|
Yes
|
TR-358
|
303-47-9 |
Ochratoxin A |
Rats |
F344/N |
Female |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/51 1/50 5/50 OR CARCINOMA 0/50 0/51 1/50 3/50
|
Neoplastic Lesions
|
Yes
|
TR-358
|
303-47-9 |
Ochratoxin A |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 1/51 6/51 10/50 OR CARCINOMA 0/50 0/51 16/51 30/50
|
Neoplastic Lesions
|
No
|
TR-358
|
303-47-9 |
Ochratoxin A |
Rats |
F344/N |
Female |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 17/50 23/51 22/50 28/50
|
Neoplastic Lesions
|
No
|
TR-465
|
77-09-8 |
Phenolphthalein |
Rats |
F344/N |
Male |
Dosed-Feed |
Adrenal Gland Medulla
|
Clear Evidence |
Clear Evidence |
PHEOCHROMOCYTOMA 17/50 34/50 34/50 34/50
|
Neoplastic Lesions
|
No
|
TR-465
|
77-09-8 |
Phenolphthalein |
Rats |
F344/N |
Female |
Dosed-Feed |
Adrenal Gland Medulla
|
Some Evidence |
Some Evidence |
PHEOCHROMOCYTOMA 3/50 11/50 9/50 2/49 OR MALIGNANT PHEOCHROMOCYTOMA 0/50 1/50 1/50 0/50 COMBINED 3/50 12/50 10/50 2/49
|
Neoplastic Lesions
|
No
|
TR-465
|
77-09-8 |
Phenolphthalein |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
HISTIOCYTIC SARCOMA 0/50 2/50 7/50 7/50; LYMPHOMA 15/50 28/50 33/5 25/50; LYMPHOMA (THYMIC ORIGIN) 1/50 9/50 10/50 7/50
|
Neoplastic Lesions
|
No
|
TR-465
|
77-09-8 |
Phenolphthalein |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
HISTIOCYTIC SARCOMA 1/50 3/50 11/50 12/49; LYMPHOMA (THYMIC ORIGIN) 0/50 4/50 7/50 2/49
|
Neoplastic Lesions
|
Yes
|
TR-465
|
77-09-8 |
Phenolphthalein |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
(SINGLE SECTIONS) ADENOMA 0/50 4/50 2/50 6/50 OR CARCINOMA 0/50 1/50 1/50 2/50 COMBINED 0/50 5/50 3/50 7/50; (SINGLE AND STEP SECTIONS) ADENOMA 1/50 10/50 15/50 15/50 OR CARCINOMA 0/50 1/50 2/50 2/50 COMBINED 1/50 10/50 16/50 16/50
|
Neoplastic Lesions
|
No
|
TR-465
|
77-09-8 |
Phenolphthalein |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Ovary
|
Clear Evidence |
Clear Evidence |
BENIGN SEX-CORD STROMAL TUMOR 0/50 7/49 6/50 5/50
|
Neoplastic Lesions
|
No
|
TR-367
|
50-33-9 |
Phenylbutazone |
Mice |
B6C3F1 |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-367
|
50-33-9 |
Phenylbutazone |
Rats |
F344/N |
Female |
Gavage |
Kidney Transitional Cell
|
Some Evidence |
Some Evidence |
CARCINOMA 0/50 0/50 2/50
|
Neoplastic Lesions
|
Yes
|
TR-367
|
50-33-9 |
Phenylbutazone |
Rats |
F344/N |
Female |
Gavage |
Kidney Tubular Cell
|
Some Evidence |
Equivocal Evidence |
ADENOMA (STEP SECTIONS) 0/50 3/50 1/50 OR CARCINOMA 0/50 1/50 0/50 COMBINED 0/50 4/50 1/50
|
May Have Been Related
|
No
|
TR-367
|
50-33-9 |
Phenylbutazone |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 0/50 0/49 3/50 OR CARCINOMA 0/50 1/49 0/50 COMBINED 0/50 1/49 3/50
|
Neoplastic Lesions
|
No
|
TR-367
|
50-33-9 |
Phenylbutazone |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 8/50 12/50 24/50 OR CARCINOMA 8/50 4/50 11/50 COMBINED 16/50 14/50 31/50
|
Neoplastic Lesions
|
No
|
TR-470
|
110-86-1 |
Pyridine |
Rats |
F344/N |
Female |
Dosed-Water |
Hematopoietic System
|
Equivocal Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 12/50 16/50 22/50 23/50
|
May Have Been Related
|
Yes
|
TR-470
|
110-86-1 |
Pyridine |
Rats |
F344/N |
Male |
Dosed-Water |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
(SINGLE SECTIONS) ADENOMA 1/50 0/48 2/50 6/49 COMBINED 1/50 1/48 2/50 6/49; (SINGLE AND STEP SECTIONS) ADENOMA 2/50 3/48 6/50 10/49 COMBINED 2/50 4/48 6/50 10/49
|
Neoplastic Lesions
|
Yes
|
TR-470
|
110-86-1 |
Pyridine |
Rats |
Wistar |
Male |
Dosed-Water |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
(SINGLE SECTIONS) ADENOMA 1/50 0/48 2/50 6/49 COMBINED 1/50 1/48 2/50 6/49; (SINGLE AND STEP SECTIONS) ADENOMA 2/50 3/48 6/50 10/49 COMBINED 2/50 4/48 6/50 10/49
|
Neoplastic Lesions
|
No
|
TR-470
|
110-86-1 |
Pyridine |
Mice |
B6C3F1 |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 37/49 39/50 43/50 34/50, CARCINOMA 13/49 23/50 33/50 41/50, HEPATOBLASTOMA 1/49 2/50 9/50 16/50 COMBINED 41/49, 42/50, 45/50, 44/50
|
Neoplastic Lesions
|
No
|
TR-470
|
110-86-1 |
Pyridine |
Mice |
B6C3F1 |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 29/50 40/50 34/49 39/50, CARCINOMA 15/50 35/50 41/49 40/50, HEPATOBLASTOMA 2/50 18/50 22/49 15/50; COMBINED 38/50, 47/50, 46/49, 47/50
|
Neoplastic Lesions
|
No
|
TR-470
|
110-86-1 |
Pyridine |
Rats |
Wistar |
Male |
Dosed-Water |
Testis
|
Equivocal Evidence |
Equivocal Evidence |
INTERSTITIAL CELL ADEMONA 5/50 6/49 4/49 12/50
|
Neoplastic Lesions
|
No
|
TR-409
|
117-39-5 |
Quercetin |
Rats |
F344/N |
Female |
Dosed-Feed |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
Yes
|
TR-409
|
117-39-5 |
Quercetin |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
(SINGLE SECTIONS) ADENOMA 0/50 0/50 0/50 3/50
(SINGLE AND STEP SECTIONS) ADENOMA 1/50 2/50 7/50 8/50
(SINGLE SECTIONS) ADENOCARCINOMA 0/50 0/50 0/50 1/50
(SINGLE AND STEP SECTIONS) OVERALL ADENOMA OR ADENOCARCINOMA 1/50 2/50 7/50 9/50
|
Neoplastic Lesions
|
No
|
TR-519
|
64742-88-7 |
Stoddard solvent (type lIC) |
Mice |
B6C3F1 |
Male |
Inhalation |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-519
|
64742-88-7 |
Stoddard solvent (type lIC) |
Rats |
F344/N |
Female |
Inhalation |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-519
|
64742-88-7 |
Stoddard solvent (type lIC) |
Rats |
F344/N |
Male |
Inhalation |
Adrenal Gland Medulla
|
Some Evidence |
Some Evidence |
BENIGN PHEOCHROMOCYTOMA 5/50 9/50 13/50 17/50 BENIGN OR MALIGNANT PHEOCHROMOCYTOMA 6/50 9/50 13/50 19/50
|
Neoplastic Lesions
|
Yes
|
TR-519
|
64742-88-7 |
Stoddard solvent (type lIC) |
Rats |
F344/N |
Male |
Inhalation |
Kidney Tubular Cell
|
Some Evidence |
Equivocal Evidence |
(STANDARD AND EXTENDED EVALUATION COMBINED) ADENOMA 3/50 2/50 3/50 7/50
|
May Have Been Related
|
No
|
TR-519
|
64742-88-7 |
Stoddard solvent (type lIC) |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 9/50 12/50 15/50 18/50
|
May Have Been Related
|
Yes
|
TR-436
|
75-65-0 |
tert-Butyl alcohol |
Rats |
F344/N |
Male |
Dosed-Water |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
(SINGLE SECTIONS) ADENOMA 1/50 3/50 4/50 2/50 OR CARCINOMA 0/50 0/50 0/50 1/50 COMBINED 1/50 3/50 4/50 3/50; (SINGLE AND STEP SECTIONS) ADENOMA 8/50 11/50 19/50 13/50 OR CARCINOMA 0/50 2/50 1/50 1/50 COMBINED 8/50 13/50 19/50 13/50
|
Neoplastic Lesions
|
No
|
TR-436
|
75-65-0 |
tert-Butyl alcohol |
Mice |
B6C3F1 |
Male |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 1/60 0/59 4/59 1/57 OR CARCINOMA 0/60 0/59 0/59 1/57 COMBINED 1/60 0/59 4/59 2/57
|
Neoplastic Lesions
|
No
|
TR-436
|
75-65-0 |
tert-Butyl alcohol |
Mice |
B6C3F1 |
Female |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Some Evidence |
Some Evidence |
ADENOMA 2/58 3/60 2/59 9/59
|
Neoplastic Lesions
|
No
|
TR-311
|
127-18-4 |
Tetrachloroethylene |
Rats |
F344/N |
Male |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LEUKEMIA 28/50 37/50 37/50
|
Neoplastic Lesions
|
No
|
TR-311
|
127-18-4 |
Tetrachloroethylene |
Rats |
F344/N |
Female |
Inhalation |
Hematopoietic System
|
Some Evidence |
Some Evidence |
LEUKEMIA 18/50 30/50 29/50
|
Neoplastic Lesions
|
Yes
|
TR-311
|
127-18-4 |
Tetrachloroethylene |
Rats |
F344/N |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/49 3/49 2/50 OR ADENOCARCINOMA 0/49 0/49 2/50 COMBINED 1/49 3/49 4/50
|
Neoplastic Lesions
|
No
|
TR-311
|
127-18-4 |
Tetrachloroethylene |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
CARCINOMA 1/48 13/50 36/50
|
Neoplastic Lesions
|
No
|
TR-311
|
127-18-4 |
Tetrachloroethylene |
Mice |
B6C3F1 |
Male |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 11/49 8/49 18/50; CARCINOMA 7/49 25/49 26/50
|
Neoplastic Lesions
|
No
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Rats |
F344/N |
Male |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA: 34/50 43/50 38/50 31/50
|
May Have Been Related
|
No
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Mice |
B6C3F1 |
Female |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
HISTIOCYTIC SARCOMA 1/48 21/48 19/47 18/48
|
Neoplastic Lesions
|
No
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Mice |
B6C3F1 |
Male |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
HISTIOCYTIC SARCOMA 0/48 12/48 7/48 7/48
|
Neoplastic Lesions
|
No
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Rats |
F344/N |
Female |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
MONONUCLEAR CELL LEUKEMIA: 16/50 31/50 23/50 36/50
|
Neoplastic Lesions
|
Yes
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Rats |
F344/N |
Female |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
SINGLE SECTIONS: ADENOMA 0/50 3/50 1/50 3/50 OR CARCINOMA 0/50 0/50 0/50 2/50 COMBINED 0/50 3/50 1/50 5/50; SINGLE AND STEP SECTIONS: ADENOMA 0/50 3/50 3/50 8/50 OR CARCINOMA 0/50 0/50 0/50 3/50 COMBINED 0/50 3/50 3/50 10/50
|
Neoplastic Lesions
|
Yes
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Rats |
F344/N |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
SINGLE SECTIONS: ADENOMA 0/50 0/50 6/50 3/50 OR CARCINOMA 1/50 0/50 2/50 0/50 COMBINED 1/50 0/50 6/50 3/50; SINGLE AND STEP SECTIONS: ADENOMA 2/50 4/50 9/50 13/50 OR CARCINOMA 1/50 1/50 2/50 0/50 COMBINED 3/50 5/50 9/50 13/50
|
Neoplastic Lesions
|
No
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 15/48 17/48 20/47 15/47 OR CARCINOMA 4/48 28/48 22/47 20/47 COMBINED 17/48 33/48 29/47 28/47
|
Neoplastic Lesions
|
No
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Mice |
B6C3F1 |
Male |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 17/48 17/48 12/48 20/48 OR CARCINOMA 11/48 20/48 33/48 26/48 COMBINED 26/48 34/48 39/48 35/48
|
Neoplastic Lesions
|
No
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Rats |
F344/N |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 4/50 5/50 6/50 OR CARCINOMA 0/50 4/50 9/50 2/50 COMBINED 0/50 7/50 12/50 8/50
|
Neoplastic Lesions
|
No
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Rats |
F344/N |
Male |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 3/50 6/50 8/50 5/50 OR CARCINOMA 1/50 1/50 10/50 3/50 COMBINED 4/50 7/50 15/50 8/50
|
Neoplastic Lesions
|
No
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Rats |
F344/N |
Male |
Inhalation |
Testis
|
Clear Evidence |
Equivocal Evidence |
INTERSTITIAL CELL ADENOMA 39/50 40/50 48/50 47/50
|
May Have Been Related
|
No
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Mice |
B6C3F1 |
Female |
Inhalation |
Vascular System (Liver)
|
Clear Evidence |
Clear Evidence |
HEMANGIOMA 0/48 5/48 2/47 1/47 OR HEMANGIOSARCOMA 0/48 27/48 27/47 34/47 COMBINED 0/48 31/48 28/47 35/47
|
Neoplastic Lesions
|
No
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Mice |
B6C3F1 |
Male |
Inhalation |
Vascular System (Liver)
|
Clear Evidence |
Clear Evidence |
HEMANGIOMA 0/48 10/48 5/48 2/48 OR HEMANGIOSARCOMA 0/48 21/48 27/48 37/48 COMBINED 0/48 26/48 30/48 38/48
|
Neoplastic Lesions
|
No
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Rats |
F344/N |
Female |
Inhalation |
Vascular System (Liver)
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/50 0/50 5/50 1/50
|
Neoplastic Lesions
|
No
|
TR-475
|
109-99-9 |
Tetrahydrofuran |
Mice |
B6C3F1 |
Male |
Inhalation |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-475
|
109-99-9 |
Tetrahydrofuran |
Rats |
F344/N |
Female |
Inhalation |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
Yes
|
TR-475
|
109-99-9 |
Tetrahydrofuran |
Rats |
F344/N |
Male |
Inhalation |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOMA 1/50 1/50 4/50 3/50 OR CARCINOMA 0/50 0/50 0/50 2/50 COMBINED 1/50 1/50 4/50 5/50
|
Neoplastic Lesions
|
No
|
TR-475
|
109-99-9 |
Tetrahydrofuran |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 12/50 17/50 18/50 31/48 OR CARCINOMA 6/50 10/50 10/50 16/48 COMBINED 17/50 24/50 26/50 41/48
|
Neoplastic Lesions
|
No
|
TR-391
|
115-96-8 |
Tris(2-Chloroethyl) Phosphate |
Mice |
B6C3F1 |
Female |
Gavage |
Harderian Gland
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 3/50 7/50 7/50 OR CARCINOMA 0/50 1/50 0/50 COMBINED 3/50 8/50 7/50
|
Neoplastic Lesions
|
No
|
TR-391
|
115-96-8 |
Tris(2-Chloroethyl) Phosphate |
Rats |
F344/N |
Female |
Gavage |
Hematopoietic System
|
Clear Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 14/50 16/50 20/50
|
May Have Been Related
|
No
|
TR-391
|
115-96-8 |
Tris(2-Chloroethyl) Phosphate |
Rats |
F344/N |
Male |
Gavage |
Hematopoietic System
|
Clear Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 5/50 14/50 13/50
|
May Have Been Related
|
Yes
|
TR-391
|
115-96-8 |
Tris(2-Chloroethyl) Phosphate |
Rats |
F344/N |
Female |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 5/50
|
Neoplastic Lesions
|
Yes
|
TR-391
|
115-96-8 |
Tris(2-Chloroethyl) Phosphate |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 5/50 24/50
|
Neoplastic Lesions
|
No
|
TR-391
|
115-96-8 |
Tris(2-Chloroethyl) Phosphate |
Mice |
B6C3F1 |
Male |
Gavage |
Kidney Tubular Cell
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 1/50 1/50 3/50
|
Neoplastic Lesions
|
No
|
TR-391
|
115-96-8 |
Tris(2-Chloroethyl) Phosphate |
Rats |
F344/N |
Female |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 1/50 1/50 1/50 OR CARCINOMA 0/50 2/50 3/50 COMBINED 1/50 3/50 4/50
|
May Have Been Related
|
No
|
TR-391
|
115-96-8 |
Tris(2-Chloroethyl) Phosphate |
Rats |
F344/N |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 1/50 2/48 3/50 OR CARCINOMA 0/50 0/48 2/50 COMBINED 1/50 2/48 5/50
|
May Have Been Related
|
No
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL PAPILLOMA OR CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Positive |
Positive |
ADENOMA OR ADENOCARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Rats |
F344/N |
Female |
Dosed-Feed |
Kidney Tubular Cell
|
Positive |
Positive |
ADENOMA
|
Neoplastic Lesions
|
Yes
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Positive |
Positive |
ADENOMA, ADENOMA OR ADENOCARCINOMA
|
Neoplastic Lesions
|
No
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(ADENOMA, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA)
|
Neoplastic Lesions
|